Did Merck just call the bottom of the life-science tools slump, or overpay for it?

On 25 June 2026, Germany's Merck KGaA agreed to buy Bio-Techne, a Minneapolis maker of the proteins, antibodiesantibodiesLab-made proteins that latch onto one specific target molecule; researchers use them to detect or isolate whatever they are studying. and lab instruments that drug researchers use by the case, for $73 a share in cash. The enterprise value, the all-in cost of owning the business, share price plus debt minus cash, is about $11.3 billion (EUR 9.9 billion). It is Merck's largest acquisition since it bought Sigma-Aldrich in 2015.

The market did the expected thing to the target and the unexpected thing to the buyer. Bio-Techne jumped about 20% to close at $70.67, closing most of the gap to the $73 offer. That is just arbitragearbitrageTraders buying a target's stock once a cash bid is announced, pushing the price up toward the fixed offer to capture the small remaining gap.: traders pulling the share price toward a cash floor that is now fixed. The more telling move is that Merck's own stock rose nearly 5%.

At roughly nine times sales, is Merck paying a top-of-cycle price for a company stuck at bottom-of-cycle growth, and what would have to come true for that to make sense?

Let us build the number from the filings rather than assert it. The price tag is $11.3 billion of enterprise value. Bio-Techne's net sales for the fiscal year that ended in June 2025 were $1,219.6 million, with organic revenue up 5%. Divide one by the other: $11.3bn divided by $1.22bn is about 9.3 times trailing sales.

The trouble is that the rent has been climbing slowly.

Merck KGaA of Darmstadt, the German chemicals and life-sciences group, unrelated to the U.S. firm Merck & Co., agreed on 25 June 2026 to acquire Bio-Techne Corporation of Minneapolis for $73.00 per share in cash. The deal, approved by both boards, carries an enterprise value of about $11.3 billion (EUR 9.9 billion) and is expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals. Merck has guided to about EUR 140 million of annual cost savings, fully in place by the third year after closing.

Bio-Techne sells into Merck's Life Science arm: reagentsreagentsConsumable biological substances such as antibodies and proteins that researchers use up in experiments and must keep reordering., antibodies and instruments that fit alongside Merck's own laboratory and bioprocessing range. The assets Merck most often names are the high-growth fringe, spatial-biology tools (the RNAscope line), multi-omics and proteomics, and good-manufacturing-practice reagents used to make cell and gene therapies, rather than the slower legacy catalog.

We pulled Bio-Techne's reported organic growthorganic growthRevenue growth from the existing business only, stripping out acquisitions and currency swings, so it shows whether the underlying business is really expanding. from every fiscal-year earnings release back to 2018. 'Organic' growth strips out acquisitions and currency swings, so it is the cleanest read on whether the underlying business is actually expanding. The picture is a boom that has deflated.

Read it left to right and the story tells itself. Before COVID, Bio-Techne compounded at 9-10% a year. The pandemic sent drug research into overdrive and growth spiked to 22%, then 17%. Then came the hangover: biopharma companies cut research budgets, demand in China sagged, and labs worked through the reagents they had panic-bought. Growth collapsed to 1% in fiscal 2024 before recovering to 5% last year.

That 5% is the number under the price, roughly half the 9-10% pace Bio-Techne ran before the pandemic. The worst is arguably past, but Merck is paying a multiple that usually attaches to companies growing much faster.

To judge whether 9.3x is rich, you need the comparison set: what other buyers paid for similar businesses since the 2021 valuation peak collapsed. We rebuilt each multiple from the deal's own enterprise value and the target's disclosed revenue, and dropped any bar we could not source.

Two things stand out. First, 9.3x is near the top of this set but not at it. Danaher paid roughly 10x for Abcam in 2023, the closest true comparable, another maker of premium antibodies and reagents. (Measured against Abcam's last full year of sales rather than its run-rate at announcement, that multiple is higher still, closer to 12x.) Either way, Bio-Techne sits just under the cycle's richest reagent deal, so 'top of the range' is better read as 'near the top.'

Second, the cleaner cyclical signal is what these multiples have not done. The Waters combination with BD's bioscience and diagnostics arm, struck in 2025 and completed in February 2026, valued that business at roughly 5x sales. Thermo Fisher's purchase of the clinical-research firm PPD went off at about 4.4x back in 2021. Neither is a pure reagents comparable, but together they show the broad market for life-science assets never reflated to its 2021 peak. Bio-Techne's 9.3x is a premium paid for a specific kind of asset, high-margin, recurring-revenue consumables, not a sign that the whole sector is hot again.

Revenue multiples can mislead, because they ignore how much profit each dollar of sales actually throws off. Bio-Techne keeps an unusually large share: its adjusted EBITDAadjusted EBITDAEBITDA with one-off or non-cash items removed, meant to show normalized, ongoing profitability; each company defines its own adjustments., a rough measure of operating cash profit, was about 35% of sales last year. So switch the yardstick from sales to profit and the deal looks far less exotic.

On Bio-Techne's fiscal-2025 adjusted EBITDA of $429.6 million, $11.3 billion works out to about 26 times profit. Add the EUR 140 million (roughly $150 million) of annual cost savings Merck says it can wring out by year three, and the effective multiple falls toward 20 times. That is squarely inside the range strategic buyers, companies buying to keep and operate, not to flip, routinely pay for durable, high-margin franchises. The catch is in the tense: the 20x exists only in the future, after the savings actually arrive. The 26x is what Merck is paying today.

One more figure gets quoted two different ways, and both are correct. They simply measure from different starting lines.

Merck's own release leads with a 36% premiumpremiumHow much more per share an acquirer pays than the stock's prior price; the figure depends entirely on which baseline date you measure against., measured against Bio-Techne's volume-weighted average price over the prior month, the average price the stock actually traded at, weighting bigger trades more. Measured against just the closing price the day before the announcement, the premium is about 24%. The 24% is the gain over yesterday's screen; the 36% is the gain over where the stock sat for a month, before takeover speculation crept into the price. Neither is wrong; a seller naturally prefers to quote the bigger one.

So the answer to the narrow question is layered. On revenue, 9.3x is a top-of-cycle-looking price for a business growing at a bottom-of-cycle 5%. On profit, after the promised savings, about 20x is unremarkable for a high-margin reagents franchise. The market's near-5% lift in Merck's shares says investors lean toward the second reading. But that is a one-day vote on price, not a verdict on value.

The bull case lives entirely in two soft numbers that are not in last year's accounts: the EUR 140m of cost savings, and a growth re-acceleration the revenue line does not yet show.

For the multiple to make sense, both have to land. Merck has to actually extract the EUR 140 million it has promised, and Bio-Techne's growth has to climb from 5% back toward the high single digits its spatial-biology, proteomics and cell-and-gene-therapy lines are supposed to deliver. If the savings arrive and growth re-accelerates by year three, 9.3x sales and 26x EBITDAEBITDAEarnings before interest, taxes, depreciation and amortization, a rough measure of the cash profit a business throws off from its day-to-day operations. will look like a smart entry near the bottom of a cycle. If neither does, the same numbers will read as a top-of-cycle price paid for a business that had merely stopped falling.